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GEC1-Opioid Receptor Binding Involves
Hydrophobic Interactions
GEC1 HAS CHAPERONE-LIKE EFFECT*□S
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Yong Chen‡, Chongguang Chen‡, Evangelia Kotsikorou§, Diane L. Lynch§, Patricia H. Reggio§,
and Lee-Yuan Liu-Chen‡1
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We demonstrated previously that the protein GEC1 (glan-
dular epithelial cell 1) bound to the human  opioid receptor
(hKOPR) and promoted cell surface expression of the recep-
tor by facilitating its trafficking along the secretory pathway.
Here we showed that three hKOPR residues (Phe345, Pro346,
and Met350) and seven GEC1 residues (Tyr49, Val51, Leu55,
Thr56, Val57, Phe60, and Ile64) are indispensable for the inter-
action. Modeling studies revealed that the interaction was
mediated via direct contacts between the kinked hydrophobic
fragment in hKOPR C-tail and the curved hydrophobic sur-
face in GEC1 around the S2 -strand. Intramolecular Leu44-
Tyr109 interaction in GEC1 was important, likely by main-
taining its structural integrity. Microtubule binding
mediated by the GEC1 N-terminal domain was essential for
the GEC1 effect. Expression of GEC1 also increased cell sur-
face levels of the GluR1 subunit and the prostaglandin EP3.f
receptor, which have FPXXM and FPXM sequences, respec-
tively.With its widespread distribution in the nervous system
and its predominantly hydrophobic interactions, GEC1 may
have chaperone-like effects for many cell surface proteins
along the biosynthesis pathway.
 opioid receptor (KOPR)2 is one of the three major types of
opioid receptors mediating effects of opioid drugs and endoge-
nous opioid peptides. Stimulation of KOPR generates many
effects in vivo, for example antinociception (especially for vis-
ceral chemical pain, antipruritis, and water diuresis (1). The
KOPR agonist nalfurafine (TRK-820) is used clinically in Swe-
den for the treatment of uremic pruritus in kidney dialysis
patients (2). Because KOPR agonists produce profound seda-
tive effects, it has been proposed that KOPR agonists may be
useful in treating mania, antagonists as anti-depressants, and
partial agonists for the management of mania depression (3).
KOPR antagonists may also be useful for curbing cocaine crav-
ing and as anti-anxiety drugs (4, 5).
KOPR, a member of the rhodopsin subfamily of the seven-
transmembrane receptor superfamily, is coupled preferentially
to pertussis toxin-sensitiveGproteins, namelyGi/o proteins (6).
KOPR has been found to interact with several non-G protein-
binding partners, such as Na,H-exchanger regulatory fac-
tor-1/ezrin-radixin-moesin-binding phosphoprotein-50 and
the  opioid receptor. These interactions have influence on sig-
nal transduction and trafficking of the receptor (7–9). By yeast
two-hybrid (Y2H) assay using the hKOPR C-tail to screen a
human brain cDNA library, we identified GEC1, also named
GABAA receptor-associated protein like 1 (GABARAPL1), to
be a binding partner of hKOPR (10).
GEC1 cDNA was first cloned as an early estrogen-regulated
mRNA from guinea pig endometrial glandular epithelial cells
by Pellerin et al. (11). Subsequently, it was cloned from other
species, including human and house mouse (12). Interestingly,
the amino acid sequences of GEC1 are completely conserved
among all these species except orangutan, in which Arg99 sub-
stitutes for His99. Northern blot and immunoblotting analyses
revealed that it has widespread tissue distribution (12–14). In
particular, GEC1 was found to be abundant in the central nerv-
ous system and expressed throughout the rat brain (14, 15).
This wide tissue distribution and the high sequence identity
across species strongly suggest that GEC1 has important bio-
logical functions in mammalian cells.
Based on sequence similarity, GEC1 is classified as amember
of microtubule-associated proteins (MAPs), which also include
GABAA receptor-associated protein (GABARAP), Golgi-asso-
ciated ATPase enhancer of 16 kDa (GATE16), GABARAP-like
3 (GABARAPL3), light chain 3 (LC3) of MAP 1A/1B, and the
yeast autophagy protein 8 (Atg8) (12, 13). Among these homo-
logues, GEC1 share the highest identity with GABARAPL3
(93%), followed by GABARAP (86%), GATE16 (61%), Atg8
(55%), and LC3 (30%).
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A growing body of evidence shows that this protein family is
closely related to two distinct biological functions. Studies
mainly on GABARAP, GATE16, and GEC1 indicate that they
promote intracellular protein trafficking by enhancing vesicle
fusion (10, 16–21). In addition, they facilitate degradation of
proteins and intracellular organelles via autophagy-related
pathways, which is bolstered largely by research on Atg8 and
LC3 (22, 23).
We previously reported that GEC1 interacted with the
hKOPRC-tail and enhanced cell surface levels of hKOPR stably
expressed in CHO cells. GEC1 expression enhances hKOPR
expression through facilitating its anterograde trafficking along
the protein biosynthesis pathwaywithout affecting degradation
of the receptor (10). This represented the first biological func-
tion reported for GEC1. Mansuy et al. (24) demonstrated that
GEC1 interacted with tubulin and promoted microtubule bun-
dling in vitro, and that green fluorescence protein-taggedGEC1
was localized in the perinuclear vesicles with a scattered pat-
tern. Our electron microscopic studies in the rat brain showed
thatGEC1was associatedwith ER,Golgi apparatus, endosome-
like vesicles, and plasma membranes and scattered in cyto-
plasm in neurons (14). In addition,N-ethylmaleimide-sensitive
factor, a protein critical for intracellular membrane-trafficking
events, binds directly to GEC1 (10).
In this study, we employed Y2H techniques to determine the
amino acid residues in both GEC1 and hKOPR C-tail involved
in the interaction. Further studies were then carried out in
mammalian cells to examine if elimination of the interaction
affected the effect of GEC1 on hKOPR expression. In addition,
we generated a molecular model of GEC1 based on the x-ray
crystal structure of GABARAP and found that the residues
involved in hKOPR binding formed hydrophobic patches on
the exterior surface ofGEC1.Moreover, we found that the cyto-
solic tail of AMPA receptor subunit GluR1 has the same
FPXXMmotif as that found in the hKOPRC-tail to be involved
in GEC1 binding and that GEC1 expression up-regulated
GluR1.
EXPERIMENTAL PROCEDURES
Materials
[15,16-3H]Diprenorphine (56 Ci/mmol) was purchased
from PerkinElmer Life Sciences. Naloxone and rabbit anti-
FLAG polyclonal antibody were purchased from Sigma. Cell
media (Dulbecco’s modified Eagle’s medium/F-12, 1:1), Opti-
MEM I reduced serum, fetal bovine serum (FBS), and Lipo-
fectamine transfection reagent were acquired from Invitrogen.
QIAquick gel extraction kit, QIAquick PCR purification kit,
and QIAprep 8 miniprep kit were acquired from Qiagen
(Valencia, CA). Materials for yeast two-hybrid assays such as
bait and prey vectors (pGBKT7 and pGADT7, respectively),
minimal SD agar base, dropout supplement, and Yeastmaker
yeast transformation system 2 kit were purchased from Clon-
tech. The following reagents were purchased from the indi-
cated companies: geneticin (G418) from Cellgro Mediatech
(Herndon, VA); horseradish peroxidase-conjugated goat anti-
rabbit, IgG horseradish peroxidase-conjugated goat anti-
mouse IgG, and Quick Ligation kit from New England Biolabs
(Beverly, MA); PfuUltra High Fidelity DNA polymerase from
Stratagene (La Jolla, CA); all restriction endonucleases and
dNTP from Promega (MadisonWI); and monoclonal antibody
against HA (HA.11) from Covance (Princeton, NJ).
The cDNA construct of the wild-type rat AMPA receptor
subunit GluR1 in pcDNA3.1 and rabbit anti-GluR1 antibody
were generous gifts from Dr. Richard Huganir (Department of
Neuroscience, The Johns Hopkins University, Baltimore). The
cDNA constructs of HA-tagged human prostaglandin receptor
EP3.f and EP3.I in pcDNA3.1 were provided by Dr. Barrie
Ashby (Department of Pharmacology, TempleUniversity, Phil-
adelphia). Rabbit anti-GEC1 polyclonal antibody (PA629p) was
generated previously (10). The following software products
were used: Prism 3.0 program from GraphPad Software Inc.
(San Diego, CA), ImageJ 1.34S from National Institutes of
Health (Bethesda), andOptiQuant (PerkinElmer Life Sciences).
Cell Lines
A clonal CHO cell line stably expressing the FLAG-hKOPR
was generated previously (25), and the Bmax value of FLAG-
hKOPR was1.9 pmol/mg protein (26). CHO cells with stable
expression of FLAG-hKOPR-F346A (residue Phe346
replaced by Ala), FLAG-hKOPR-P347A, FLAG-hKOPR-
M350A, rGluR1, HA-hEP3.f, and HA-hEP3.I were estab-
lished similarly. For cells stably expressing hKOPR mutants,
further screening using [3H]diprenorphine binding assay
was performed to obtain cells with similar Bmax values as that
of FLAG-hKOPR. All cells were cultured in 10-cm culture
dishes in Dulbecco’s modified Eagle’s medium/F-12 medium
supplemented with 10% FBS, 0.2 mg/ml geneticin in a
humidified atmosphere consisting of 5% CO2 and 95% air at
37 °C.
Transient Expression of GEC1
Lipofectamine-mediated DNA transfection experiments
were performed by following the manufacturer’s protocol with
some modifications. GEC1-pcDNA3.1/Hygro() was previ-
ously constructed (10). Twenty four hours before transfection,
1.8–2.0 million cells stably expressing FLAG-hKOPR were
seeded on each 10-cmPetri dish. On the experiment day, trans-
fection was carried out with 40 l of Lipofectamine (1 mg/ml),
10g of theDNAconstruct or the plasmid vector (control), and
6ml of Opti-MEMmedium per 10-cm dish. At 16 h after trans-
fection, medium was replaced by 10 ml of Opti-MEM contain-
ing 10% FBS. Forty hours following transfection, the cells were
harvested for further experiments.
Co-immunoprecipitation of hKOPR and GEC1-(38–117)
The cDNA construct of wild-type or mutant FLAG-hKOPR
or the vector pcDNA3.1 was co-transfected with HA-GEC1-
(38–117) at a ratio of 5:5 (g) into one 100-mm dish of CHO
cells. Forty hours after transfection, two dishes of cells (2 107)
were collected and solubilized in 1 ml of TTSEC (0.5% Triton
X-100, 50 mM Tris, pH 7.5, 0.15 M NaCl, 1 mM EDTA, and
protease inhibitormixture fromRoche Applied Science) for 1 h
at 4 °C. Cell lysates were cleared by centrifugation at 105  g
followed by filtration through a 0.2-m filter. One ml of super-
natant was incubated with 20 l of anti-FLAG-agarose beads
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(M2, Sigma) overnight at 4 °C. The beads were then washed
three times with TTSEC containing 1% Triton X-100 and
extracted in 40 l of loading buffer (4% SDS, 50 mM Tris, pH
6.25, and 100 mM dithiothreitol). Samples were separated on
12% SDS-PAGE and transferred to Immobilon (Millipore), and
immunoblotting of HA-GEC1-(38–117) and FLAG-hKOPR
was performed with rabbit anti-HA antibody and rabbit anti-
FLAG antibody, respectively, and followed by enhanced chemi-
luminescence. Transfection and co-immunoprecipitation of
HA-GEC1-(38–117) or its mutants with FLAG-hKOPRwere
performed similarly. The program OptiQuant (PerkinElmer
Life Sciences) was used to analyze the immunoblotting
results.
[3H]Diprenorphine Binding to hKOPR in Intact Cells
Saturation binding was performedwith six concentrations of
[3H]diprenorphine (0.1, 0.2, 0.4, 0.6, 1.0, and 2.0 nM) and
150,000 cells/tube in duplicate in 1 ml of PBS buffer containing
1 mg/ml bovine serum albumin at room temperature for 60
min. Ten M naloxone was used to define nonspecific binding.
The Kell program (known as EBDA previously) was used to
analyze data and to obtain the Bmax andKd values. Binding with
1 nM [3H]diprenorphine was performed with 200,000 cells/
tube in a similar manner. Naloxone (10 M) was employed to
define the nonspecific binding for total receptors as described
previously (10).
SDS-PAGE and Immunoblotting
Cells were harvested using Versene buffer, solubilized in 2
Laemmli sample buffer, and subjected to Tricine-SDS-PAGE
on 8% separating gel as described previously (10). The sepa-
rated protein bands were transferred to Immobilon-P polyvi-
nylidene difluoride transfer membranes on which immuno-
blotting was carried out with primary antibodies, horseradish
peroxidase-linked secondary antibody, and SuperSignal West
Pico Chemiluminescent reagents (10). Primary antibodies used
were rabbit polyclonal anti-FLAG (F7425) antibody (0.8mg/ml,
1:5000), rabbit polyclonal anti-GluR1 antibody (1:5000) or
mouse monoclonal anti-HA antibody (1 mg/ml, 1:5000). The
protein bands were visualized and then digitalized with Fuji
LAS-1000 Plus gel documentation system (Fuji Film, Tokyo,
Japan). Expression level of transfected GEC1 protein was eval-
uated by immunoblotting as described above except using 15%
Tricine/SDS-PAGE, boiled (100 °C, 5 min) sample solution,
and rabbit polyclonal anti-GEC1 (PA629p) antibody (0.49
g/ml, 1:7500).
Y2H Assays
The general strategies were to use different hKOPR-C tail
(334–380) or GEC1-(38–117) mutants to narrow down (trun-
cation mutants) and then to define (double and single alanine
substitution mutants) the amino acid residues that account for
GEC1-hKOPR interaction. GEC1-(38–117) is a truncated
GEC1, which was the form originally identified to bind the
hKOPR C-tail in our previous Y2H studies (10).
For determining the amino acid residues inGEC1 involved in
hKOPR binding, GAL4 yeast two-hybrid system was employed
to evaluate interaction between GEC1 mutants and hKOPR-
(334–380). GEC1 mutant cDNA was generated using PCR and
inserted into the prey vector pGADT7 containing a LEU2 selec-
tion marker for yeast, which was then transformed into yeast
strain Y187 that is auxotrophic for adenine (Ade), tryptophan
(Trp), histidine (His), and leucine (Leu). Human KOPR-(334–
380) cDNA was inserted into the bait vector pGBKT7 contain-
ing a TRP1 nutritional marker for yeast selection that was then
transformed into yeast strain AH109 that is also auxotrophic
for Ade, Trp, His, and Leu. After selecting transformants on
SD/Leu and SD/Trp media, respectively, the two positive
haploids were mated, and growth status of the diploids on
media with different stringency was monitored and evaluated.
The amino acids in hKOPR C-tail involved in GEC1 binding
were determinedwith the samemethod except that the plasmid
constructs of hKOPR-(334–380) mutants/pGBKT7 and
GEC1-(38–117)/pGADT7 were used.
Plasmid Construction for Y2H—N and C termini of GEC1-
(38–117) were truncated by an increment of 10 and 2 residues
via a series of PCRs. The PCRproducts digestedwith restriction
enzymes EcoRI and BamHI were ligated into the prey vector
pGADT7. After delineating the hKOPR binding region using
aforementioned GEC1-(38–117) truncation mutants, single
alanine substitution mutants were generated within the 40–67
and 109–113 fragments of GEC1-(38–117) by overlap PCR to
define the residues required for the GEC1-hKOPR interaction.
With the same strategy, five-amino acid truncation, double and
single alanine substitution mutants of hKOPR-(334–380) in
pGBKT7 (NdeI/SalI) were established. All the resulting DNA
plasmids were purified using QIAprep SpinMiniprep kit. DNA
sequences of the insertswere verified by theUniversity of Penn-
sylvania DNA sequencing facility.
Transformation of Yeast Cells—Transformation of yeast with
constructs was carried out using standard PEG/LiAc protocol
as described in our previous publication (10).
Mating of Yeast Cells—The twomating partner strains, Y187
andAH109, were transformedwith prey (GEC1/pGADT7) and
bait (hKOPR-C/pGBKT7) plasmids, respectively. Transfor-
mants were selected using the proper SD dropoutmedium, and
the mating was conducted in 96 six-well plates. For both trans-
formants, a single colony (2–3 mm, less than 1 month old) was
suspended in 1ml of 2YPDA/kanamycinmedium.Twentyl
each of the Y187 and the AH109 cell suspension was added to
one well containing 200l of 2 YPDAmediumwith kanamy-
cin (10g/ml) andmixed well. The plate was then incubated at
30 °C for 16–18 h on an orbital shaker set at 200 rpm. Mating
reactions were monitored for diploid formation using phase-
contrast microscope (27). The mating culture was diluted with
physiological saline and then plated in a volume of 100 l onto
SD medium with three levels of stringency: double dropout
(2DO) SD/Leu/Trp, triple dropout (TDO) SD/Leu/
Trp/His, and quadruple dropout (QDO) SD/Leu/Trp/
His/Ade. The plates were incubated upside-down at 30 °C
for 5–7 days to obtain well separated colonies with a diameter
of 1–3 mm. Dilution factor for the mating culture was adjusted
so that the resulting colony number of the diploid on the 2DO
plate was 200–400.
Assessment of the Protein-Protein Interaction—Throughout
the yeast two-hybrid assays, the mating mixture of GEC1-(38–
GEC1-KOPR Interaction
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117)/pGADT7 and hKOPR-C(334–380)/pGBKT7 was used as
the positive control and GEC1-(38–117)/pGADT7 combined
with pGBKT7() as the negative control. Plasmid pGBKT7()
was derived from the pGBKT7 vector of which the sequence
between the NdeI site and SalI site (in the multiple cloning
sites) was deleted. Five to 7 days after yeast mating, the colony
number on the SD agar plates was counted using software
ImageJ 1.34S. For each mating reaction, the diploid number on
TDO and QDO plates was normalized against that on 2DO
plate. Then the normalized numbers were compared with its
counterparts in the positive control group. The protein-protein
interaction between GEC1-(38–117) and hKOPR C-tail was
considered to be strong (), moderate (), weak (), or
absent () if the resulting percentages were larger than 80%,
between 30 and 80%, between 5 and 30%, or less than 5%,
respectively.
Structural Modeling of GEC1
Initial Model—Although no crystal structure of GEC1 has
been published, GEC1 shares 86% identity with GABARAP. So
the 1.75-Å resolution GABARAP x-ray crystal structure (Pro-
tein Data Bank code 1GNU) (28) served as template here for an
initial (united atom) GEC1 model. The GABARAP/GEC1
sequence alignment presented in Chen et al. (10) (also see Fig.
9A) was used as input to Modeler (version 9.1) (29, 30). The
GEC1 model with the lowest objective function out of 100
models generated was chosen for further refinement. Hydro-
gens were added to the model using Maestro version 8.0.110
(Schro¨dinger, LLC, New York), with a short minimization
performed to optimize the hydrogen positions. Energy min-
imization was performed using Macromodel version 9.5 (31)
and the OPLS2005 all atom force field. A distance-depend-
ent dielectric, 8.0-Å extended nonbonded cutoff, 20.0-Å
electrostatic cutoff, and 4.0-Å hydrogen bond cutoff were
used. The minimization consisted of 500 steps (Polak-Ribier
conjugate gradient method) with backbone and side chain
heavy atoms fixed.
Molecular Dynamics of Apo-GEC1 in an Aqueous Environ-
ment—NAMD2 (32) molecular dynamics simulations were
used to relax the initial GEC1 model in an aqueous environ-
ment. 10 Å of waters in each direction of the protein were
added using the VMD Solvate package, and the VMDMeadi-
onize plugin was employed to achieve electroneutrality.
NAMD2 calculations used the CHARMM27 parameter set
(33–35) and the TIP3P model for water. Periodic boundary
conditions were employed with
the long range coulombic electro-
static potential treated with the
Particle-Mesh Ewald summation
method (36). The Lenard-Jones
potential was smoothly cut off
between 8.5 and 10 Å. The
NAMD2 simulation used the
r-RESPA multiple time step algo-
rithm with a time step of 4 fs for
long range electrostatic forces, 2 fs
for short range nonbonded forces,
and 1 fs otherwise. The simulation
cell was minimized for 20 ps (5 ps
with heavy atoms fixed and 15 ps
with all atoms unrestrained).
Using Langevin coupling to a heat
bath, the cell was warmed to 310 K
(NVT ensemble) in 10° increments
for 20 ps with the backbone con-
strained using a 0.5 kcal/mol Å2
harmonic force. 1.25 ns of equili-
bration (NPT; 310 K/1 atm) was
performed in 0.25-ns runs with a
decreasing backbone harmonic
constraint for each run (0.5, 0.25,
0.10, 0.05, and 0.0 kcal/mol Å2).
FIGURE 1.Mapping the GEC1-binding motif in the C-tail of hKOPR using Y2H assays. A, summary of Y2H
results. Truncation anddouble and single alanine substitutionmutants of hKOPRC-tailwere examined for their
abilities to interact with GEC1-(38–117). The hKOPR C-tail mutants were generated by PCR, constructed into
GAL4-binding domain vector pGBKT7, and transformed into yeast strain AH109. The GEC1-(38–117) was con-
structed into GAL4 activation domain vector pGADT7 and transformed into yeast strain Y187. The two trans-
formed yeast strainsmated, and thematingmixtureswere culturedon SD/Trp/Leu (2DO), SD/Trp/Leu/
His (TDO), and SD/Trp/Leu/His/Ade (QDO) agar plates. The resulting diploid colonies were counted,
and the ratio of thenumber of colony-formingunits on TDO/QDOplates over colony-formingunits on the 2DO
plate was used to evaluate the interaction strength of each pair of GEC1-(38–117) and hKOPR C-tail mutant.
Assessment details were described under “Experimental Procedures.” The experiments were performed three
times with reproducible results. Results on truncation and double alanine substitution mutants are shown in
supplemental Fig. 1.B, aminoacid sequencealignmentof C-tails of thehumanopioid receptors demonstrating
that the defined GEC1 binding region is hKOPR-specific.
TABLE 1
Effect of GEC1 expression on 3Hdiprenorphine binding to the KOPR
stably transfected into CHO cells
Cells were transiently transfected with GEC1 or the vector pcDNA3.1. Forty hours
later, saturation binding of 3Hdiprenorphine (six concentrations ranging from 0.1
to 2 nM, including 1 nM) to the receptor was performed, andKd andBmax values were
calculated. The percent change in KORP expression level measured by 1 nM
3Hdiprenorphine binding was determined, which is consistent with that in Bmax
value. 3HDiprenorphine (1 nM) binding was therefore chosen to measure the
changes of receptor expression in all subsequent experiments. Data are expressed as
means  S.E. (n  3). ** indicates p 	 0.01 compared with the control group by
Student’s t test.
Cells
transfected
with
Kd
Bmaxfmol/106
cells
% increase of control
Bmax 1 nM3Hdiprenorphine
nM
Control vector 0.13 0.01 70.00 0.67
GEC1 0.17 0.02 129.90 0.83** 85.6 2.3 84.4 3.1
GEC1-KOPR Interaction
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Once the protein was equilibrated, a 10-ns production run
was initiated (NPT; 310 K/1 atm).
Conformational Memories—The Monte Carlo/simulated
annealing method, Conformational Memories (CM) (37–
39), was used to explore (in the presence of GEC1) the low
free energy conformations of an octapeptide from the C ter-
minus of the hKOPR that contains the GEC1-binding motif,
FPXXM (CFPLKMRM). The GEC1 model, taken from the
MD trajectory, was that frame in which key KOPR C-termi-
nal interaction residues were most exposed. The CHARMM
force field was employed for this calculation. In the CM
exploratory phase, the peptide was positioned 59 Å above
GEC1 at T 3000 K. Then the peptide was drawn toward the
GEC1 surface in 18 steps (3.28 Å/step) as the temperature
was decreased to T  310 K (18 steps). 102 runs were per-
formed per temperature with a run
consisting of 50,000 steps applied
to all peptide torsion and bond
angles, allowing them to vary
180 and 8°, respectively. The
CM biased-annealing phase,
began at T  749.4 K, cooling to
310 K in nine steps. The peptide
was drawn to the GEC1 surface
using a planar restraint on the
peptide center of mass (k  0.025
kcal/mol Å2), and the center of
mass was confined spatially using
a cylindrical restraint (k  0.02
kcal/mol Å2; 15.7 Å diameter cir-
cle at the protein surface, T  310
K). To account for electrostatic
screening in water, a distance-de-
pendent, nonlinear (sigmoidal)
screened Coulomb potential as
described by Hassan et al. (40, 41)
(average screening parameter
1.0367) was employed, with the
dielectric constant decreased from
80 to 1, based on the distance
between the peptide center of
mass and the protein surface.
The 102 octapeptide-GEC1
complexes (holo-GEC1) output at
310 K were screened using the cri-
teria that the GEC1-binding motif
(FPXXM) of the hKOPR C-termi-
nal peptide (residues Phe2, Pro3,
and Met6) is critical for GEC1
interaction and that the first
octapeptide residue (Cys1), being a
putative palmitoylation site, needs
to be unobstructed. The complex
that best met these criteria was
then equilibrated in water via
NAMD2 MD simulations.
MolecularDynamicsofHolo-GEC1
in Aqueous Environment—The
NAMD2 settings used for apo-GEC1 detailed above were
used to equilibrate holo-GEC1 in water, with the exception
that the water box extended 12 Å from the complex surface
in all directions. After minimization (heavy atoms fixed), the
simulation cell was warmed to 310 K in 10° increments for 20
ps (heavy atoms fixed), and then run for 1 ns with harmonic
constraints to maintain the complex while the system was
solvated. Because the equilibrated apo-GEC1 was used for
the complex, a heavy atom harmonic constraint of 1.0 kcal/
mol Å2 was employed for GEC-1, whereas a 0.5 kcal/mol Å2
harmonic constraint was placed on the following: (i) the pep-
tide Phe2, Pro3, and Met6 C- atoms; (ii) the most extreme
Phe2 and Pro3 carbons; and (iii) the Met6 sulfur and its adja-
cent methylene carbon to maintain the CM identified com-
plex. The system was minimized (NVT), and then a 1.5-ns
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FIGURE 2. A, F346A, P347A, and M350A mutations in the hKOPR C-tail reduced co-immunoprecipitation of
GEC1-(38–117). GEC1-(38–117)was co-transfected intoCHOcellswithwild-type (wt) or amutant FLAG-hKOPR
or the control vector. The receptors were immunoprecipitated (IP) with anti-FLAG (M2)-agarose beads 40 h
after transfection. The SDS-PAGE was performed, and the GEC1-(38–117) (GEC1 co-IPed, 1st row) and hKOPR
(receptor IPed, 2nd row) were detected with immunoblotting (IB) with anti-HA antibody and anti-FLAG anti-
bodies, respectively. The ratios of density of GEC1-(38–117) over receptor were normalized against that of
wild-type receptor and are shown in the graph at right. Each value represents the mean S.E. of three inde-
pendent experiments. *, p 	 0.05, and **, p 	 0.01 compared with wild-type group using one-way ANOVA
followed by Tukey’s post hoc test. B, effects of GEC1 on expression of the wild-type and alanine-substituted
mutants (F346A, P347A, M350A, and R351A) of FLAG-hKOPR. Wild-type hKOPR and its alanine-substituted
mutants were cloned in pcDNA3.1 and then stably expressed in CHO cells. Wild-type and mutated receptors
wereexpressedat similar levels (1.9pmol/mgprotein). GEC1or thevectorpcDNA3.1 (control)was transiently
transfected into these cells. [3H]Diprenorphine (1nM)binding tohKOPRwasperformedon intact cells 40hafter
transfection. Data were expressed as the percentage of increase in [3H]diprenorphine binding in GEC1-trans-
fected cells compared with the control cells. Each value represents the mean  S.E. of three independent
experiments. ***, p	 0.005 compared with wild-type group using one-way ANOVA followed by Tukey’s post
hoc test.
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equilibration was followed by a 5-ns production run (NPT;
310 K/1 atm) using the same constraints as the warm up and
equilibration.
Data Analysis
All quantitative datawere present asmean S.E. if theywere
derived from at least 3 experiments. For comparison of mul-
tiple groups, the datawere analyzed by one-way analysis of vari-
ance (ANOVA) followed by a Tukey post hoc test. If the p value
less than 0.05, the difference was defined as significant. All sta-
tistical analyses were performed using GraphPad Prism 3.0.
RESULTS
Effect of GEC1 on KOPR Expression—Results of saturation
binding of [3H]diprenorphine, an antagonist, revealed that
GEC1 expression resulted in 85% increase in Bmax value
compared with the control, but there was no change in the
Kd value (Table 1).When binding was conducted with1 nM
[3H]diprenorphine, a concentration close to saturation,
the percentage increase in KOPR binding was 84%. We
therefore performed binding with 1 nM [3H]diprenorphine,
rather than saturation binding, in the subsequent
experiments.
Determination of GEC1-binding Sequence in the hKOPR
C-tail—Two series of truncation mutants were generated by
deleting five amino acids incrementally from the N terminus
and the C terminus, respectively, and their interactions with
GEC1-(38–117) were examined. The fragment 344FCFPLK-
MRMERQSTSRV360 appeared to be necessary for the inter-
action (supplemental Fig. I). We then generated double ala-
nine substitution mutants of the hKOPR C-tail within this
fragment, and their interactions
with GEC1-(38–117) were exam-
ined. We found that the residues
346FP347 and 350MR351 were essen-
tial (supplemental Fig. I). Single
alanine substitution mutations
were subsequently carried out,
and Phe346, Pro347, and Met350
were found to be critical (Fig. 1A).
In addition, Phe344, Cys345, Leu348,
and Lys349 appeared to be involved
in the GEC1-hKOPR interaction,
but they were not as important
(Fig. 1A). Thus, the GEC1-binding
sequence was defined as FPXXM.
Sequence alignment (Fig. 1B) of
the C-tails of human opioid recep-
tors (, , and ) revealed that this
sequence was unique to the KOPR
among the opioid receptors.
We then investigated if muta-
tions in the FPXXM sequence in
the hKOPR C-tail affected interac-
tion of the hKOPR with GEC1 in
CHO cells. Three single alanine
substitution FLAG-hKOPR mu-
tants, F346A, P347A, and M350A,
were constructed, and CHO cells
stably expressing each mutant
were established. We have previ-
ously demonstrated that although
GEC1 immunoprecipitated with
hKOPR, the signals appeared to be
weak (10), most likely because of
the strong interaction of GEC1
FIGURE 3. Permutations of the GEC1-binding motif in the hKOPR C-tail.
Phe346, Pro347, and Met350 in the hKOPR C-tail were replaced, one at a time,
with the indicated amino acids. The interactions of the hKOPR C-tail mutants
with GEC1-(38–117) were evaluated in Y2H assays as described in Fig. 1. The
experiments were performed three times with similar results.
FIGURE 4.Mapping of the residues in GEC1 involved in binding to hKOPR using Y2H assays. Serial trun-
cationand substitutionmutants ofGEC1-(38–117)wereexamined for their ability to interactwithhKOPRC-tail.
GEC1-(38–117) mutants were generated by PCR, constructed into GAL4 activation domain vector pGADT7,
and transformed into yeast strain Y187. The hKOPR C-tail was constructed into GAL4-binding domain vector
pGBKT7 and transformed into yeast strain AH109. The two transformed yeast strains mated, and the mating
mixtures were selected, and interaction strength was evaluated as described in Fig. 1. The experiments were
performed three times with reproducible results. Results on truncation and double alanine substitution
mutants are shown in supplemental Fig. II.
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with microtubules via its N-terminal region. The tubulin-
binding domain of GEC1 was mapped to the fragment
(amino acids 1–22) (24). We found that the amount of
GEC1-(38–117) immunoprecipitated with the hKOPR was
higher than that of GEC1 (data not shown); therefore, GEC1-
(38–117) was used in the co-immunoprecipitation experi-
ments. GEC1-(38–117) was transiently transfected, and co-
immunoprecipitation was examined. As shown in Fig. 2A,
substitutions of Phe346, Pro347, or Met350 with Ala signifi-
cantly reduced the amount of GEC1-(38–117) co-immuno-
precipitated with FLAG-hKOPR.
We next determined whether mutations in the FPXXM
sequence in the hKOPR C-tail influenced up-regulation of
KOPR by GEC1 in CHO cells. As shown in Fig. 2B, the enhanc-
ing effect of GEC1 on hKOPR expression was greatly reduced
by F346A, P347A, andM350Amutations (p	 0.005) but not by
R351A mutation. In Y2H assay, R351A substitution in the
hKOPR C-tail did not affect its
interaction with GEC1 (see above).
Thus, the data from Y2H assays,
co-IP, and functional studies indi-
cate that Phe346, Pro347, and Met350
are critical for the interaction
between GEC1 and hKOPR, which
results in up-regulation of the
hKOPR.
Permutations of the FPXXM
Sequence—We further character-
ized structural requirements of the
GEC1-binding motif. We generated
the following single mutants in the
hKOPR C-tail: mutations of Phe346
to Tyr, Trp, His, and Leu; Pro347 to
Gly; and Met350 to Cys, Ser, Thr,
Asp, Asn, Leu, and Lys. We found
that, at the position 346, having Tyr
and Trp substitutions resulted in
robust interaction with GEC1, but
His or Leu did not (Fig. 3), indicat-
ing that the aromatic ring is indis-
pensable. For the 347 position, sub-
stitution of Pro with the simplest
and most flexible residue glycine
totally abolished the binding, dem-
onstrating that that the kink struc-
ture is critical for the twoproteins to
bind. Change of Met350 to acidic,
basic, or polar residue eliminated
GEC1-hKOPR interaction, but
substitution with the hydrophobic
residue Leu had little effect on the
interaction. Therefore, lipophilic
residue at the 350 position is impor-
tant for GEC1 binding. Therefore,
the GEC1-interacting FRXXM
sequence can be expanded to (Phe,
Tyr, Trp(Pro-XX)Met, Leu), which
is a kink-producing hydrophobic
fragment. As Leu and Ile are very similar, it is possible that
Met350 can be replaced with Ile.
Determination of hKOPR-binding Domain in GEC1-(38–
117)—GEC1-(38–117) was employed as the starting construct
because it was found to interact with the hKOPR-C tail in the
original Y2H screening (10). With the 10-amino acid trunca-
tion mutants of GEC1-(38–117), we found that at least the
(38KARVPDLDKRKYLVPSDLTV57) fragment in the N-termi-
nal region and the (108AYSDESVYGK117) fragment in the
C-terminal region were required for the interaction (supple-
mental Fig. II). Serial double-truncation mutants of GEC1-
(38–117) within these two regions were generated and exam-
ined. We found that, at least, the amino acid residues 44LD45,
50LVPS53, and 108AYSD111 were required for GEC1 to interact
with the hKOPR (supplemental Fig. II).
Alanine substitution scanning studies in the fragments
40RVPDLDKRKYLVPSDLTVGQFYFLIRKR67 and 109YSDES113
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FIGURE 5. A, V57A or F60A mutation in GEC1-(38–117) GEC1 reduced its co-immunoprecipitation with FLAG-
hKOPR. Wild-type GEC1-(38–117) or its mutant was co-transfected into CHO cells with wild-type FLAG-hKOPR
or the control vector. The receptors were immunoprecipitated (IP) using anti-FLAG (M2)-agarose beads 40 h
after transfection. SDS-PAGEwas performed, and GEC1-(38–117) and themutants (GEC1 co-IPed, 1st row) and
FLAG-hKOPR (receptor IPed, 2nd row) were detected with immunoblotting (IB). The ratios of density of GEC1-
(38–117) or the mutants over FLAG-hKOPR were normalized against that of wild-type GEC1-(38–117) and are
shown in the graph at right. Each value represents the mean S.E. of three independent experiments. *, p	
0.05 compared with wild-type group using one-way ANOVA followed by Tukey’s post hoc test. B, effects of
single alanine substitution of the critical residues in the hKOPR-binding motif on the GEC1-induced enhance-
ment in FLAG-hKOPR expression. Wild-type GEC1 and its alanine-substituted mutants were cloned in
pcDNA3.1 and then transiently transfected into CHO cells stably expressing FLAG-hKOPR. Forty hours after
transfection, [3H]diprenorphine (1nM) binding tohKOPRwasperformedon intact cells. Datawere expressed as
the percentage of increase in [3H]diprenorphine binding in GEC1-transfected cells compared with the control
cells that were transfectedwith the vector pcDNA3.1. Each value represents themean S.E. of five independ-
ent experiments. *, p	 0.05, and **, p	 0.01 comparedwithwild-type group using one-way ANOVA followed
by Tukey’s post hoc test.
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were performed. The Y2H results showed that residues Tyr49,
Val51, Leu55, Thr56, Val57, Phe60, and Ile64 were indispensable
for GEC1-(38–117) to bind to the hKOPR C-tail (Fig. 4). In
addition, five other residues, Leu44, Leu50, Tyr61, Arg65, and
Tyr109, appeared to be involved (Fig. 4).
We then investigated if single alanine-substituted full-length
GEC1 mutants interacted with the hKOPR in CHO cells, using
V57A and F60A as the representatives. As shown in Fig. 5A,
alanine substitution of Val57 or Phe60 in GEC1 greatly reduced
its interaction with hKOPR. Subsequently, we examined if ala-
nine substitution at Tyr49, Val51, Leu55, Thr56, Val57, Phe60, or
Ile64 affected the effect of GEC1 on hKOPR expression. Tran-
sient expression of each of the seven mutants resulted in less
up-regulation of hKOPR than the wild-type GEC1, and the
decreases caused by alanine substitution mutation at Leu55,
Thr56, Val57, and Phe60 were statistically significant (Fig. 5B).
Other Receptors Containing FPXXM or a Similar Sequence—
A search of the Swiss Protein Database revealed that many pro-
teins contain FPXXM sequence. The C-tail of AMPA receptor
subunit GluR1 contains such a sequence (Fig. 6A). Using CHO
cells stably transfected with GluR1, we found that transient
expression of the wild-type GEC1, but not V57A GEC1,
enhanced GluR1 expression (Fig. 6A).
Prostaglandin receptor EP3.f has a FPXM sequence in its
C-terminal domain (Fig. 6B), which is similar, but not iden-
tical, to FPXXM. In CHO cells stably transfected with EP3.f,
expression of wild-type GEC1, but not the V57A mutant,
enhanced the level of the EP3.f receptor (Fig. 6B). In con-
A. 
GluR1 C-tail: 
EFCYKSRSESKRMKGFCLIPQQSINEAIRTSTLPRNSGAGASGGGGSGENGRVVSQD FPK
SMQSIPCMSHSSGMPLGATGL 
 
  
B. 
EP3.f C-tail: 
FCQMRKRRLREQAPLLPTPTVIDPSRFCAQPFRWFLDLSFPAMSSSHPQLPLTLASFKLL
REPCSVQLS 
 
EP3.I C-tail: 
FCQIRYHTNNYASSSTSLPCQCSSTLMWSDHLER  
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FIGURE 6. Effect of GEC1 on expression of GluR1 and EP3.f, which contain the GEC1-bindingmotif or a similar sequence. Amino acid sequences of the
cytosolic C-tails of AMPA receptor subunit GluR1 (A), prostaglandin receptor EP3.f, and EP3.I (B) are shown. The matched patterns (FPXXM or FPXM) are
underlined and in boldface. Effects of GEC1 or its V57A mutant on expression of GluR1 (A) and HA-EP3.f and HA-EP3.I prostaglandin (B) receptors stably
expressed in CHO cells were examined. Cells were transiently transfected with GEC1 or its V57A mutant. Forty hours after the transfection, immunoblottings
were performed in duplicate with 200,000 cells in Laemmli sample buffer (per lane). GluR1, GEC1 and prostaglandin receptors were detected with rabbit
anti-GluR1, rabbit anti-GEC1, and mouse monoclonal anti-HA antibodies, respectively. Each value represents the mean S.E. of three independent experi-
ments. *, p	 0.05, and **, p	 0.01 compared with wild-type group using one-way ANOVA followed by Tukey’s post hoc test.
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trast, GEC1 had no impact on expression of the EP3.I, a
splice variant of the EP3.f that does not have the FPXM
sequence (Fig. 6B). Thus, it is very likely that GEC1 directly
interacted with GluR1 and EP3.f through similar sequences
in the receptor C-tails.
Molecular Model of GEC1—The x-ray crystal structure of
GABARAP (28) (ProteinData Bank code 1GNU)was employed
as a template for the GEC1 model given the high sequence
similarity (94%) and identity (86%) of GEC1 with GABARAP.
Among the 100models produced by
Modeler, the one with the lowest
objective function was chosen for
further refinement (see Fig. 7A).
The GEC1 model is composed of
an N-terminal helical region (resi-
dues 1–25) that is highly basic and a
core structure (residues 27–117)
with a typical -grasp ubiquitin-like
folding. The basic N-terminal
domain of GEC1 consisting of two
-helices (1 and 2) has been sug-
gested to be responsible for mediat-
ing direct interaction with microtu-
bules. Following residue Pro26, the
core domain of GEC1 structure
includes four -strands (strands
1–4) and two -helices (helices 3
and 4), the two middle strands
(strands 1 and 4) parallel to each
other, and the two outer strands
(strands 2 and 4) anti-parallel to
their neighboring inner strands,
respectively. -Helix 3 is located
between -strands 2 and 3, whereas
-helix 4 is between-strands 3 and
4. Fig. 7B shows spatial orientations
of residues of primary importance
for GEC1 interaction with the
hKOPR C terminus inmagenta and
those of secondary importance in
cyan.
Molecular Dynamics of Apo-
GEC1 in an Aqueous Environment;
KOPR C-tail Binds to Hydrophobic
Patches on the Surface of GEC1—
The 10-ns production run trajec-
tory of GEC1 in an aqueous envi-
ronment was analyzed to identify a
GEC1 conformation that most
exposed key residues identified to
be critical for binding. We found
that when the Leu63 1 torsion
angle was in g (60°), the binding
site was more exposed than when
this torsion was trans (180°). In
addition, GEC1 clearly underwent
a “breathing” motion during the
simulation, permitting the identi-
fication of a conformation that most exposed key residues.
This conformer is illustrated in Fig. 7, C and D, which show
two views of the GEC1 surface. Residues found to be of pri-
mary importance for GEC1 interaction with the KOPR C-tail
are colored magenta in Fig. 7, C and D, (Tyr49, Val51, Leu55,
Thr56, Val57 (not visible in the views), Phe60 and Ile64),
whereas residues found to be of secondary importance
(Leu44, Leu50, Tyr61, Arg65, and Tyr109 (not visible in the
views)) are colored cyan.
FIGURE 7.Molecularmodel of GEC1. A,molecular model of GEC1 created by using the structure of GABARAP
as the template. B, view of residues that are critical for (magenta color) and involved in (cyan) interaction with
thehKOPRC-tail as determinedby theY2Hassays. Spatial orientations of side chains (in stick format inmagenta
and cyan) of these residues are displayed.C andD,GEC1model derived from theNAMD2 trajectory. Themodel
represents that frame from the trajectory in which key residues were most exposed. D, model in C has been
rotated by 90° about the x axis. C and D, color schemes of residues are identical to B; residues of primary
importance are shown inmagenta (Tyr49, Val51, Leu55, Thr56, Val57 (not visible in either view), Phe60, Ile64), and
residues of secondary importance are shown in cyan (Leu44, Leu50, Tyr61, Arg65, and Tyr109 (not visible in either
view)). E, intramolecular interaction between Leu44 and Tyr109. This image results from a 90° clockwise rotation
about the vertical y axis from the view in B. Side chains of these two residues may interact through van der
Waals forces, which may contribute to structural stability of GEC1.
GEC1-KOPR Interaction
JANUARY 16, 2009•VOLUME 284•NUMBER 3 JOURNAL OF BIOLOGICAL CHEMISTRY 1681
 by guest on O
ctober 2, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Each residue that is critical for interaction has a hydrophobic
side chain or an aromatic ring, except Thr56. As shown in Fig.
7B, all side chains of these amino acids, with the exception of
the isopropyl group ofVal57, appeared to orient in similar direc-
tions, forming a curved hydrophobic surface (around the S2
-strand) (Fig. 7, C and D). In addition, the lipophilic isobutyl
group of Leu50 in-strand 2 appeared to enlarge this hydropho-
bic surface of GEC1, although its side chain did not point to the
same direction. This curved face in GEC1 likely fits well with
the kinked hydrophobic FPXXMmotif in hKOPRC-tail. More-
over, the side chains of Tyr61 and Arg65 in -helix 3 were very
close spatially and appeared to be on the same GEC1 surface
(Fig. 7, B–D).
The Y2H data revealed that Leu44 and Tyr109 of GEC1 were
important for its interactionwith the hKOPRC-tail. Themodel
of GEC1 showed that part of the Leu44 side chain was exposed
to the surface, whereas the entire residue of Tyr109 was in the
interior of the protein (Fig. 7, B–D). Fig. 7E clearly demon-
strated that Leu44 andTyr109 likely have a direct intramolecular
interaction between their hydrophobic side chains, which may
act tomaintain the three-dimensionalGEC1 conformation that
is essential for interaction.
The molecular dynamics output of the hKOPR C-terminal
octapeptide (CFPLKMRM)-GEC1 complex identified by Con-
formational Memories is illustrated in Fig. 8. In this complex,
the peptide FPXXM-binding motif residues are illustrated at
the top in tube display (Fig. 8A), and below (Fig. 8B) these res-
idues are contoured at their van der Waals radii, with Phe2
colored orange, Pro3 colored green, and Met6 colored yellow. It
is clear here that the peptide FPXXM-binding motif residues
contact the Tyr49/Val51/Leu55/Thr56/Phe60/Ile64 region of
GEC1 (Fig. 8B, coloredmagenta). The energy of interaction of
these important amino acids with the GEC1 model was found
to be dominated by van derWaals forces. The interaction ener-
gies were110.25 kcal/mol for Phe2,68.42 kcal/mol for Pro3,
and109.48 kcal/mol for Met6.
Effects of GABARAP and GATE16 on Expression of
FLAG-hKOPR—Sequence alignment (Fig. 9A) demonstrated
that all seven critical residues were completely conserved
betweenGEC1 andGABARAP, and that, except similar residue
at position 55, all the other six amino acids were identical
between GEC1 and GATE16. We examined whether these two
proteins enhanced FLAG-hKOPR expression like GEC1. As
shown in Fig. 9B, both GABARAP and GATE16 greatly
enhanced the expression of FLAG-hKOPR. However, GATE16
up-regulated hKOPR to a significantly lower extent thanGEC1.
Tubulin-binding Domain Is Important for GEC1 to Promote
hKOPR Expression—Microtubule is one type of cytoskeletons
that determine organelle positions and control intracellular
transport. GEC1-(38–117) does not have the first 37 amino
acids and thus lacks the tubulin-binding domain (24). Com-
pared with the full-length GEC1 (Fig. 9), GEC1-(38–117)
caused a significantly lower extent of hKOPR up-regulation
(p 	 0.01), indicating that binding to tubulin cytoskeleton is
important for the effect of GEC1 on hKOPR expression. How-
ever, the possibility cannot be excluded that truncation causes
changes in three-dimensional GEC1 conformation that may
affect GEC1-hKOPR binding.
DISCUSSION
Hydrophobic Interactions Mediate GEC1-hKOPR Binding—
We found that seven residues, Tyr49, Val51, Leu55, Thr56, Val57,
Phe60, and Ile64, spanning from -strand 2 to -helix 3, were
indispensable for GEC1 to bind to the hKOPR, whereas five
other residues, Leu44, Leu50, Tyr61, Arg65, and Tyr109, were
involved in the interaction, but to lesser extent. GABARAP-
based model of GEC1 demonstrates a hydrophobic patch on
the surface of GEC1 formed by Tyr49, Val51, Leu55, Thr56,
Phe60, and Ile64 (around the S2 -strand), which is extended by
Leu50 (Fig. 7). Tyr61 and Arg65 formed another small patch.
Because of the lipophilic nature of the GEC1-binding sequence
in hKOPR C-tail, FPXXM, it is very likely that the interaction
resulted from hydrophobic contacts between the two proteins.
Studies on the GABARAP crystal structure also suggest a
hydrophobic surface consisting of the residues Ile21, Pro30,
Tyr49, Leu50, Val51, Leu55, Phe60, Leu63, and Phe104, which is
required for formation of head-to-tail GABARAP oligomer
(42). X-ray crystal structure of GATE-16 showed similar
exposed hydrophobic patches formed by Ile21, Pro30, Tyr49,
Leu50, Val51, Pro52, Ile55, Trp62, Ile63, and Phe104. This is the
largest conserved patch of surface between GATE-16 and yeast
Atg8 andwas predicted to be functionally important in protein-
protein interactions (43). Comparison between these three
hydrophobic surfaces shows striking conservation of residue
FIGURE 8. A and B, molecular dynamics output of the hKOPR C-terminal
octapeptide-GEC1 complex identified by Conformational Memories. The
octapeptide containing the FPXXM GEC1-binding motif is shown on the
surface of GEC1 in tube display with F2 in orange, P3 in green, and M6 in
yellow. B, those same amino acids are displayed contoured at their van der
Waals radii.
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components. It is likely that the hydrophobic patches on
GABARAP and GATE-16 interact with the lipophilic FPXXM
motif in the hKOPR C-tail in a similar manner.
The Y2H data revealed that Leu44 and Tyr109 of GEC1 were
important for its interaction with the hKOPR C-tail (Fig. 4),
which is likely because of their interaction (Fig. 7E) inmaintain-
ing structural integrity. Thus native
conformations are essential for
GEC1 to bind hKOPR C-tail.
GABARAP and GATE16 Also
Enhanced hKOPR Expression—
GABARAP and GATE16 up-regu-
lated hKOPR but to lower extents
than GEC1. These results indicate
that these three proteins are redun-
dant in their functions, at least to
some extent. This inference is
strongly supported by the finding
that deletion of GABARAP in mice
did not influence expression and
subcellular distribution of the
GABAA receptor (44). GEC1 inter-
acts with the 2 subunit of the
GABAA receptor (24) and may have
similar effects on this receptor as
GABARAP.
GATE16 increased hKOPR ex-
pression to a significantly lower
extent than GEC1 and GABARAP
(Fig. 9). Because the residues in
GEC1 critical for binding the KOPR
C-tail are highly identical, except
Leu55 inGEC1 and Ile55 inGATE16,
the difference may stem from dis-
similarity in their three-dimen-
sional structures. There are differ-
ences between GATE-16 and
GABARAP in the putatively flexible
C-terminal residues and smaller dif-
ferences in helix 2 and loop regions
(28, 42, 43, 45, 46).
Microtubules Are Involved in
GEC1-induced Enhancement in
hKOPR Expression—We have
demonstrated by pulldown tech-
niques that GEC1 interacts
directly with tubulin (10). Mansuy
et al. (24) defined the tubulin-
binding motif in GEC1 to be the
fragment (amino acids 1–22) in
the N-terminal domain, similar to
the (amino acids 1–27) fragment
in GABARAP (42). The x-ray crys-
tal structures of GABARAP,
GATE-16, and MAP-LC3 showed
that the tubulin-binding domains
contain two helices (H1 and H2)
(28, 42, 43, 45–47). The regions in
all these proteins have high contents of basic residues, which
are thought to be important for binding to the highly acidic
C-terminal region of tubulin via ionic interaction (48). The
observations that GEC1-tubulin binding is salt-sensitive and
is abolished in the presence of high salt (400 mM NaCl) are
consistent with the ionic nature of GEC1-tubulin interaction
FIGURE9.EffectsofGEC1and itsanaloguesonFLAG-hKOPRexpression.A,aminoacid sequencealignment
of GEC1, GABARAP, and GATE16 showing the highly conserved nature of the 12 GEC1 residues involved in
interaction with hKOPR. B, GEC1 up-regulated FLAG-hKOPR to a higher extent than GABARAP, GATE16, and
GEC1-(38–117). Ten g of vector, GEC1, GEC1-(38–117), GABARAP, or GATE16 cDNA was transfected, and
receptor binding assayswere conducted 40 h later. Results are expressed asmean S.E. of three experiments.
*, p	 0.05, and **, p	 0.01 compared with GEC1 group using one-way ANOVA followed by Tukey’s post hoc
test. C, immunoblotting of GABARAP family proteins and truncated GEC1. Immunoblotting of proteins at 40 h
after transfection was conducted. Two hundred thousand cells in Laemmli sample buffer (per lane) were
loaded and resolved by 15% Tricine/SDS-PAGE. Proteins were detected by immunoblotting with polyclonal
anti-GEC1 antibody, which cross-reacts with GABARAP and GATE16 in immunoblotting (14).
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(24). GEC1 has been demonstrated to enhance tubulin
assembly and microtubules bundling (24).
As shown in Fig. 9, deletion of the first 37 amino acids at the
N-terminal region of GEC1 greatly reduced its influence on
hKOPR expression. Thus, microtubule-based cytoskeletal
structures are important for the effect of GEC1 on hKOPR
expression. Similarly, the tubulin binding region of GABARAP
is important for its effect on clustering of GABAA receptors
(49). Therefore, GEC1 not only interacts with tubulin to pro-
mote microtubule bundling but also functions as a linker
betweenhKOPRand cytoskeleton to facilitate anterograde traf-
ficking of the receptor.
Possible Oligomerization of GEC1—The crystal structure of
GABARAP indicates there is a head-to-tail GABARAP oli-
gomer formed via interactions between the N-terminal six
residues of one molecule and the hydrophobic patch (around
the S2 -strand) of an adjacent molecule (42). Nymann-
Andersen et al. (50) found that GABARAP formed
homodimers through the amino acids 41–51. These 11 resi-
dues are also involved in GABARAP-GABAA receptor inter-
action (51), and they partially contribute to formation of the
highly conserved hydrophobic surface near the S2 -strand
(42, 43). Considering the high degree of homology between
GABARAP and GEC1, it is reasonable to postulate that
GEC1 may form homodimers or homo-oligomers and het-
erodimers or hetero-oligomers with GABARAP, which may
provide platforms for receptor interactions.
GEC1 Binds to Other Cell Surface Receptors—We defined
347FPXXM351 in the hKOPR C-tail to be critical for interacting
with GEC1. Among opioid receptors, only KOPR has this
sequence and is the only one of which expression is enhanced
by GEC1 (10). Expression of FPXXM-containing AMPA recep-
tor subunit GluR1 and FPXM-containing prostaglandin recep-
tor EP3.f was enhanced by GEC1, but not that of EP3.I, which
does not have a similar sequence. These results, coupled with
the widespread tissue distribution of GEC1 (14), support the
notion that GEC1may function to promote cell surface expres-
sion of many integral membrane proteins that contain FPXXM
or a similar sequence in their cytosolic domains.
GEC1 has been shown to bind to the GABAA receptor 2
subunit (24). The fragment in the GABAA receptor 2 subunit
involved in GABARAP binding was mapped to 394–411
(RTGAWRHGRIHIRIAKMD) in the second intracellular loop
of the long form (16). Notably, there is no FPXXM sequence in
the GABAA receptor 2 subunit, in or outside of the
GABARAP-binding fragment, suggesting that GEC1 may bind
to the 2 subunit via a different sequence within this fragment
or even a different part of the subunit. The binding interface of
GEC1 for theGABAA receptor2 subunit is likely to involve the
hydrophobic patches on the surface. Thus, it can then be
inferred that if the interacting protein has a hydrophobic patch
that can complement the GEC1 hydrophobic surface, the pro-
tein may bind GEC1, regardless whether it has FPXXM
sequence or not.
By phage display screening of a randomized peptide library,
Mohrluder et al. (52) identified peptides that bound
GABARAP.Among the peptides identified, therewas a consen-
sus sequence of W(V/I)(F/Y)(V/L)(P/Q). Interestingly, 394–
411 of the GABAA receptor 2 subunit, identified to be the
fragment interacting with GABARAP (16), does not contain
this sequence. Neither does the KOPR C-tail. These findings
further support the notion that hydrophobic interactions, not
specific amino acid sequences, are the main driving force for
GEC1 and GABARAP to bind their partners.
Conclusion—We have demonstrated that the residues criti-
cal for hKOPRbinding form a curved hydrophobic patch on the
surface of GEC1, which interacts with FPXXM, and that hydro-
phobic interaction is the major force driving binding between
GEC1 and hKOPR C-tail. GEC1 is likely to bind to other mol-
ecules by hydrophobic interactions, evenmoleculeswithout the
FPXXM sequence. Our study strongly suggests an expanding
set of GEC1-binding cell surface receptors and a broader func-
tional importance than previously expected. Thus, GEC1 may
have chaperone-like effects for many molecules. GEC1 mRNA
has been shown to be up-regulated by estrogen (11, 53); there-
fore, GEC1may be important in sex differences of some biolog-
ical functions.
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